Transcription Factor Sequestration by Polyglutamine Proteins

Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 648)

Abstract

In polyglutamine diseases including Huntington’s disease, the causative gene products containing expanded polyglutamine form nuclear aggregates in neurons. Recent studies have identified several transcriptional factors, which interact with and are sequestered by expanded polyglutamine aggregates in neurons. Further, altered expression of many genes has been shown in several polyglutamine disease models. These observations suggest an involvement of transcriptional dysregulation in pathological process of these diseases. In this chapter, we introduce several methods to examine the interaction of transcriptional factors with and their sequestration by expanded polyglutamine proteins in vitro and in vivo.

Key words

Polyglutamine Huntington’s disease Huntingtin Transcriptional factor Sequestration Aggregate Western blot analysis Filter trap assay Immunofluorescence microscopy EMSA 

References

  1. 1.
    The Huntington’s Disease Collaborative Research and Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72:971–983CrossRefGoogle Scholar
  2. 2.
    Landles C, Bates GP (2004) Huntingtin and the molecular pathogenesis of Huntington’s disease. Fourth in molecular medicine review series. EMBO Rep 5:958–963PubMedCrossRefGoogle Scholar
  3. 3.
    Li SH, Li XJ (2004) Huntingtin-protein interactions and the pathogenesis of Huntington’s disease. Trends Genet 20:146–154PubMedCrossRefGoogle Scholar
  4. 4.
    Harjes P, Wanker EE (2003) The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem Sci 28:425–433PubMedCrossRefGoogle Scholar
  5. 5.
    Luthi-Carter R, Hanson SA, Strand AD, Bergstrom DA, Chun W, Peters NL, Woods AM, Chan EY, Kooperberg C, Krainc D, Young AB, Tapscott SJ, Olson JM (2002) Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum Mol Genet 11:1911–1926PubMedCrossRefGoogle Scholar
  6. 6.
    Chan EY, Luthi-Carter R, Strand A, Solano SM, Hanson SA, DeJohn MM, Kooperberg C, Chase KO, DiFiglia M, Young AB, Leavitt BR, Cha JH, Aronin N, Hayden MR, Olson JM (2002) Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington’s disease. Hum Mol Genet 11:1939–1951PubMedCrossRefGoogle Scholar
  7. 7.
    Kotliarova S, Jana NR, Sakamoto N, Kurosawa M, Miyazaki H, Nekooki M, Doi H, Machida Y, Wong HK, Suzuki T, Uchikawa C, Kotliarov Y, Uchida K, Nagao Y, Nagaoka U, Tamaoka A, Oyanagi K, Oyama F, Nukina N (2005) Decreased expression of hypotha-lamic neuropeptides in Huntington disease transgenic mice with expanded polyglutamine-EGFP fluorescent aggregates. J Neurochem 93:641–653PubMedCrossRefGoogle Scholar
  8. 8.
    Sugars KL, Rubinsztein DC (2003) Transcriptional abnormalities in Huntington disease. Trends Genet 19:233–238PubMedCrossRefGoogle Scholar
  9. 9.
    Riley BE, Orr HT (2006) Polyglutamine neurodegenerative diseases and regulation of transcription: assembling the puzzle. Genes Dev 20:2183–2192PubMedCrossRefGoogle Scholar
  10. 10.
    Cha JH (2000) Transcriptional dysregulation in Huntington’s disease. Trends Neurosci 23:387–392PubMedCrossRefGoogle Scholar
  11. 11.
    Yamanaka T, Miyazaki H, Oyama F, Kurosawa M, Washizu C, Doi H, Nukina N (2008) Mutant Huntingtin reduces HSP70 expression through the sequestration of NF-Y transcription factor. EMBO J 27:827–839PubMedCrossRefGoogle Scholar
  12. 12.
    Doi H, Mitsui K, Kurosawa M, Machida Y, Kuroiwa Y, Nukina N (2004) Identification of ubiquitin-interacting proteins in purified polyglutamine aggregates. FEBS Lett 571:171–176PubMedCrossRefGoogle Scholar
  13. 13.
    Busch A, Engemann S, Lurz R, Okazawa H, Lehrach H, Wanker EE (2003) Mutant huntingtin promotes the fibrillogenesis of wild-type huntingtin: a potential mechanism for loss of huntingtin function in Huntington’s disease. J Biol Chem 278:41452–41461PubMedCrossRefGoogle Scholar
  14. 14.
    Scherzinger E, Lurz R, Turmaine M, Mangiarini L, Hollenbach B, Hasenbank R, Bates GP, Davies SW, Lehrach H, Wanker EE (1997) Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90:549–558PubMedCrossRefGoogle Scholar
  15. 15.
    Mosser DD, Theodorakis NG, Morimoto RI (1988) Coordinate changes in heat shock element-binding activity and HSP70 gene transcription rates in human cells. Mol Cell Biol 8:4736–4744PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Laboratory for Structural NeuropathologyRIKEN Brain Science InstituteSaitamaJapan
  2. 2.Special Postdoctoral Researchers ProgramRIKENSaitamaJapan

Personalised recommendations